Search
PF-04457845
go.drugbank.com/drugs/DB12012InvestigationalPF-04457845 is under investigation in Fear Conditioning. PF-04457845 has been investigated for the treatment of Tourette Syndrome and Cannabis Dependence.
PF-04634817
go.drugbank.com/drugs/DB14955InvestigationalPF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects).
PF-07038124
go.drugbank.com/drugs/DB19143InvestigationalPF-07038124 is under investigation in clinical trial NCT05298033 (Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo).
Sacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigationalMetastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (...
Chloral hydrate
go.drugbank.com/drugs/DB01563ApprovedIllicitInvestigationalVet approvedIt is no longer considered useful as an anti-anxiety medication.
CYNK-001
go.drugbank.com/drugs/DB15722InvestigationalCYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.
ATG-101
go.drugbank.com/drugs/DB17162InvestigationalATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors
Synonyms: PD-L1/4-1BB bispecific antibodyTechnetium Tc-99m pertechnetate
go.drugbank.com/drugs/DB09314ApprovedInvestigationalFollowing intravenous injection, single photon emission computed tomography (SPECT) is performed to detect the gamma ray emmitted by the decay of Technetium-99m to Technetium-99.
Palladium Pd-103
go.drugbank.com/drugs/DB15016ExperimentalPalladium Pd-103 is under investigation in clinical trial NCT00247312 (Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial).
Zimlovisertib
go.drugbank.com/drugs/DB15143InvestigationalPF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).